Tech Center 1600 • Art Units: 1628
This examiner grants 32% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17924661 | THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS | Non-Final OA | The Regents of the University of California |
| 19210983 | CDK INHIBITORS | Non-Final OA | GENENTECH, INC. |
| 19210611 | CDK INHIBITORS | Non-Final OA | GENENTECH, INC. |
| 19210825 | CDK INHIBITORS | Non-Final OA | GENENTECH, INC. |
| 19319108 | COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR QUALITY WEIGHT LOSS | Final Rejection | VERU INC. |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 19181999 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | Non-Final OA | The Board of Supervisors of Louisiana State University and Agriculture and Mechanical College |
| 18036596 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | H. Lundbeck A/S |
| 18186698 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | Non-Final OA | New York University |
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | Non-Final OA | The United States Government as Represented by the Department of Veterans Affairs |
| 16105396 | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | Final Rejection | Neurocrine Biosciences, Inc. |
| 18025252 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GRAFT VERSUS HOST DISEASE COMPRISING THIAMINE DERIVATIVES | Non-Final OA | Kyungpook National University Industry-Academic Cooperation Foundation |
| 18017339 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18242560 | Combination Antibacterial Composition and Short-Course Antibacterial Regimen | Final Rejection | The Global Alliance for TB Drug Development, Inc. |
| 15765310 | COMBINATION ANTIBACTERIAL COMPOSITION AND SHORT-COURSE ANTIBACTERIAL REGIMEN | Final Rejection | The Global Alliance for TB Drug Development, Inc. |
| 17706183 | THE USE OF PARAXANTHINE TO REDUCE EXERCISE-INDUCED MENTAL FATIGUE | Final Rejection | PX ING, LLC |
| 18261097 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | Non-Final OA | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD. |
| 18259236 | BORATE DERIVATIVE AND USES THEREOF | Non-Final OA | Reistone Biopharma Company Limited |
| 18201674 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | Non-Final OA | TES Pharma S.r.l. |
| 18034390 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE AND AUTOIMMUNE DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE, COMPRISING EXTRACT DERIVED FROM CENTIPEDA MINIMA | Non-Final OA | D-NATURE CO., LTD. |
| 17907394 | USE OF BERBERINE ANALOG AND JAK INHIBITOR IN TREATMENT OF INFLAMMATORY DISEASES OF GASTROINTESTINAL TRACT | Non-Final OA | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. |
| 18029089 | Nicotinic Acid Derivative A With Anti-Inflammation and Anti-Platelet Aggregation Activities, and Use Thereof | Non-Final OA | Chongqing Academy of Chinese Materia Medica |
| 18044978 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | Final Rejection | Astex Pharmaceuticals, Inc. |
| 18022948 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | Non-Final OA | MDI Biological Laboratory |
| 17389001 | Standardized Bioflavonoid Composition for Regulation of Homeostasis of Host Defense Mechanism | Non-Final OA | Unigen, Inc. |
| 18019379 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | Non-Final OA | Global Blood Therapeutics, Inc. |
| 18000941 | NEW USE OF RABEXIMOD | Non-Final OA | Cyxone AB |
| 18056475 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | Final Rejection | Relmada Therapeutics, Inc. |
| 17341027 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | Final Rejection | Berg LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy